Observational Study
Copyright ©The Author(s) 2017.
World J Hepatol. Apr 18, 2017; 9(11): 551-561
Published online Apr 18, 2017. doi: 10.4254/wjh.v9.i11.551
Figure 1
Figure 1 Outcomes of 223 patients inititating telaprevir- or boceprevir-based triple therapy. SVR: Sustained virological response.
Figure 2
Figure 2 Classification and regression trees analysis of baseline factors associated with sustained virologic response. SVR: Sustained virologic response; HCV: Hepatitis C virus.
Figure 3
Figure 3 Treatment outcome stratified by low and high baseline platelet count. Treatment outcomes of patients with platelets ≤ 13.5 × 104/μL and > 13.5 × 104/μL are shown in a stacked column graph. The SVR rate in the low platelet group was 28% vs 53% in the high platelet group. SVR: Sustained virologic response.

  • Citation: Bichoupan K, Tandon N, Martel-Laferriere V, Patel NM, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D, Linderman M, Olson W, Perumalswami PV, Schiano TD, Odin JA, Liu LU, Dieterich DT, Branch AD. Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. World J Hepatol 2017; 9(11): 551-561
  • URL: https://www.wjgnet.com/1948-5182/full/v9/i11/551.htm
  • DOI: https://dx.doi.org/10.4254/wjh.v9.i11.551